Treating Erectile Dysfunction in Patients with High Testosterone from Exogenous Supplementation
In men with ED who have elevated testosterone from exogenous supplementation, stop the testosterone therapy and initiate PDE5 inhibitor monotherapy as first-line treatment, since supraphysiologic testosterone levels do not improve erectile function and may suppress the hypothalamic-pituitary-gonadal axis. 1, 2
Key Management Principles
Discontinue Exogenous Testosterone
- Exogenous testosterone supplementation suppresses gonadotropins from the hypothalamic-pituitary axis and does not effectively restore or improve sexual function in most men. 3
- The failure of testosterone therapy to improve ED occurs even when circulating androgen levels are elevated, indicating no universal cause-and-effect relationship between testosterone levels and erectile function in this population. 3
- Recent high-quality evidence from 2024 demonstrates that testosterone replacement therapy improves sexual desire and activity but does not improve erectile function itself (moderate certainty of evidence). 4, 2
Initiate PDE5 Inhibitor Therapy
- All men with ED should be offered an FDA-approved oral PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) as first-line treatment unless contraindicated. 1
- PDE5 inhibitors have been extensively studied in nearly 250,000 men and show similar efficacy across agents in the general ED population. 1
- The dose should be titrated to provide optimal efficacy, with clear instructions provided to maximize benefit. 1
Critical Pitfall to Avoid
Do not combine testosterone therapy with PDE5 inhibitors in men with elevated testosterone. The combination approach is only indicated for men with documented hypogonadism (total testosterone <300 ng/dL with symptoms) who have failed PDE5 inhibitor monotherapy. 5, 6, 7 In your patient with already-elevated testosterone from supplementation, this combination is inappropriate and potentially harmful.
Assess for True Hypogonadism After Washout
- If ED persists after stopping exogenous testosterone and optimizing PDE5 inhibitor therapy, reassess testosterone levels after an appropriate washout period (typically 3-6 months depending on formulation). 8
- True testosterone deficiency is defined as total testosterone <300 ng/dL with presence of symptoms and signs. 1
- In men over 60 years, measure both total testosterone and calculated free testosterone with SHBG, as 17.2% of ED patients have normal total testosterone but low free testosterone due to elevated SHBG. 9
- Only consider testosterone replacement if documented hypogonadism is present after washout and PDE5 inhibitor optimization has failed. 5, 7
Address Cardiovascular Risk
- ED is a substantial independent risk marker for cardiovascular disease, as strong a predictor as cigarette smoking or family history of myocardial infarction. 1
- Communicate this increased cardiovascular risk to the patient and his primary care provider so appropriate referrals and interventions can be implemented. 1
Consider Psychological Factors
- Psychological factors (depression, anxiety, relationship conflict) may be primary or secondary contributors to ED. 1
- For men with predominantly psychogenic ED, offer referral to a psychotherapist as either an alternative or adjunct to medical treatment. 1
Fertility Considerations
- If the patient desires future fertility, be aware that exogenous testosterone causes suppression of spermatogenesis and can result in azoospermia. 8
- Recovery of spermatogenesis after discontinuing testosterone may take months and can be facilitated with hCG or selective estrogen receptor modulators if needed. 8